GlassScriptPhysician profile
Vincent James Riesgo
NPI 1689170540
$1,018.38
in general payments reported to CMS, 2019-2025
9 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $135 · 2023: $409 · 2024: $194 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.38 | 2020-2025 | Tezspire, Farxiga |
| Penumbra, INC. | $141.72 | 2025 | Indigo System |
| Alexion Pharmaceuticals, INC. | $115.02 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $108.84 | 2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.43 | 2023 | Jardiance |
| Silk Road Medical, INC. | $95.59 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Ethicon INC. | $79.17 | 2024 | Monarch Platform |
| Novo Nordisk INC | $78.14 | 2020 | |
| Baxter Healthcare | $16.09 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Riesgo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.